JNJ 61187165

Drug Profile

JNJ 61187165

Alternative Names: Ad26 RSV FA2; Ad26.RSV.FA2; JNJ-61187165-AAA; JNJ61187165

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Crucell Holland
  • Developer Janssen Vaccines and Prevention B.V
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2016 Crucell Holland completes a phase I trial for Respiratory syncytial virus infections (In volunteers) in USA (NCT02561871)
  • 01 Sep 2015 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention, In volunteers) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top